Leflunomide Mylan

Leflunomide, the active ingredient in Leflunomide Mylan, is an immunomodulatory agent presented as an oral tablet for oral use. It belongs to the disease‑modifying antirheumatic drug (DMARD) class and works by modulating immune cell activity. It is indicated for the treatment of rheumatoid arthritis and psoriatic arthritis in adult patients.

GNH USA supplies Leflunomide Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Leflunomide is a disease‑modifying antirheumatic drug that targets inflammatory pathways in autoimmune arthritis.

Rheumatoid arthritis: reduces joint inflammation, pain, and structural damage. Psoriatic arthritis: improves joint symptoms and may alleviate skin lesions. Adult patients with active disease: helps control disease activity and maintain functional ability.

Leflunomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Diarrhea: mild to moderate gastrointestinal upset. - Nausea: occasional feeling of sickness. - Elevated liver enzymes: mild increase in hepatic laboratory values. - Hypertension: rise in blood pressure.

Serious or Rare Side Effects: - Severe liver injury: risk of hepatitis or liver failure. - Bone marrow suppression: possible anemia, leukopenia, or thrombocytopenia. - Stevens‑Johnson syndrome: rare severe skin and mucosal reaction.

Before initiating therapy, several safety considerations should be evaluated.

- Liver function monitoring: obtain baseline tests and repeat periodically. - Blood pressure assessment: monitor for hypertension during treatment. - Avoid in severe hepatic impairment: contraindicated in patients with significant liver disease. - Use caution in pregnancy: drug is contraindicated due to teratogenic risk. - Discontinue if serious adverse events occur: stop therapy and seek medical evaluation. - Store at room temperature: keep in the original container, protect from moisture.

Leflunomide can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Warfarin: increased risk of bleeding. - Live vaccines: reduced efficacy and possible infection. - Strong CYP1A2 inducers (e.g., rifampin): markedly lower leflunomide plasma levels.

Moderate Interactions (Monitor Closely): - Methotrexate: additive hepatotoxic potential. - NSAIDs: may enhance blood pressure elevation and renal effects.